Abstract
In women aged ≥ 30 years, Human Papillomavirus testing will replace cytology for primary cervical screening. We compared Hybrid Capture 2 (HC2), cobas, CLART, and APTIMA HPV assays with cytology on 2869 SurePath samples from women undergoing routine screening at 30-65 years in Copenhagen, Denmark. Women with cytological abnormalities were managed according to routine recommendations, with 92% completeness. Those with cytology-normal/HPV-positive samples (on any of the four assays) were invited for repeated cytology and HPV testing in 1.5 year, and 58% had additional testing. HPV testing detected more ≥ CIN3 than cytology (HC2: 35, cobas, CLART: 37, APTIMA: 34, cytology: 31), although statistically the differences were not significant. Cobas and CLART detected significantly more ≥ CIN2 than cytology (cobas, CLART: 49, cytology: 39). The proportion of women with false-positive test results (positive test results without ≥ CIN3) varied between 3.3% with cytology and 14.9% with cobas. All HPV assays led to significantly more false-positive tests, whereas compared to HC2 cobas and CLART were associated with a significantly higher and APTIMA with a significantly lower proportion. Detection of CIN1 was particularly increased for the t...Continue Reading
References
Dec 11, 1996·International Journal of Cancer. Journal International Du Cancer·L RozendaalC J Meijer
Nov 30, 2006·International Journal of Cancer. Journal International Du Cancer·Matejka ReboljDik Habbema
Mar 13, 2008·British Journal of Cancer·O Ingemann-HansenLk Petersen
Oct 30, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anne SzarewskiJack Cuzick
Apr 8, 2009·The Lancet Oncology·Véronique BouvardUNKNOWN WHO International Agency for Research on Cancer Monograph Working Group
Nov 11, 2009·Nature Reviews. Clinical Oncology·Elsebeth Lynge, Matejka Rebolj
Jan 22, 2010·The Lancet Oncology·Philip E Castle, Hormuzd A Katki
Jan 22, 2010·The Lancet Oncology·Guglielmo RoncoUNKNOWN New Technologies for Cervical Cancer screening (NTCC) Working Group
Jul 16, 2010·British Journal of Cancer·M Rebolj, E Lynge
Oct 14, 2010·International Journal of Cancer. Journal International Du Cancer·Joseph MonsonegoJennifer S Smith
Nov 3, 2010·Gynecologic Oncology·Benny KirschnerJette Junge
Dec 15, 2010·Journal of Clinical Microbiology·Samuel RatnamAdrian Lear
Dec 25, 2010·Journal of Medical Virology·Angela PistaAna Oliveira
Aug 4, 2011·Scandinavian Journal of Public Health·Beth Bjerregaard, Ole B Larsen
Aug 26, 2011·The Lancet Oncology·Philip E CastleCatherine M Behrens
Sep 2, 2011·Journal of Clinical Microbiology·D A M HeidemanP J F Snijders
Oct 5, 2011·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Matejka ReboljElsebeth Lynge
Dec 20, 2011·The Lancet Oncology·Dorien C RijkaartChris J L M Meijer
Sep 29, 2012·Current Pharmaceutical Design·Matejka ReboljElsebeth Lynge
Dec 5, 2012·Vaccine·Mario PoljakMarc Arbyn
Jan 15, 2013·Vaccine·Bryan GoldmanJesper Bonde
Jan 22, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Lucybeth NievesJerome Belinson
Feb 2, 2013·British Journal of Cancer·J CuzickA Szarewski
Mar 14, 2013·PloS One·Belén LloverasSergi Serrano
Mar 28, 2013·PloS One·Sarah PreislerJesper Bonde
Jul 6, 2013·The Journal of Molecular Diagnostics : JMD·Matejka ReboljElsebeth Lynge
Nov 7, 2013·Lancet·Guglielmo RoncoUNKNOWN International HPV screening working group
Jan 28, 2014·PloS One·Matejka ReboljJesper Bonde
Jul 30, 2014·BMC Infectious Diseases·Jesper BondeCarsten Rygaard
Jan 13, 2015·Gynecologic Oncology·Thomas C WrightTeresa L Wright
Citations
Nov 30, 2016·BMC Cancer·Cornelis Johannes Jacobus HuijsmansAdrianus Johannes Christiaan van den Brule
Jun 3, 2017·Cancer Cytopathology·Yimin GeDina R Mody
Jun 1, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L de ThurahM Rebolj
Jan 20, 2018·International Journal of Cancer. Journal International Du Cancer·Inge M C M de KokMarjolein van Ballegooijen
Sep 28, 2017·Diagnostic Cytopathology·Rosario GranadosTeresa Alcaide
Mar 16, 2018·Journal of Lower Genital Tract Disease·Yimin GeDina R Mody
Jul 21, 2017·Journal of Clinical Microbiology·J U H LamJ Bonde
Aug 19, 2016·Journal of Clinical Microbiology·Matejka ReboljElsebeth Lynge
Jun 17, 2016·Journal of Clinical Microbiology·Ditte EjegodJesper Bonde
Mar 11, 2018·BMC Cancer·Mette TranbergBerit Andersen
Mar 11, 2020·BMJ Open·Georgie WestonElisabeth J Adams
Sep 14, 2017·Cytopathology : Official Journal of the British Society for Clinical Cytology·M ReboljJ Bonde
Jan 20, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Yimin GeDina R Mody
Apr 25, 2019·BMC Cancer·Juan GagoSilvina Arrossi
Aug 15, 2019·British Journal of Cancer·Matejka ReboljUNKNOWN HPV Pilot Steering Group
Sep 24, 2020·Scientific Reports·Pernille Thordal LarsenSisse Helle Njor
Nov 15, 2017·British Journal of Cancer·J U H LamJ Bonde
Nov 20, 2016·Acta Obstetricia Et Gynecologica Scandinavica·Elina VirtanenEeva Auvinen
Oct 11, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Berit AndersenHans Svanholm
Oct 19, 2020·International Journal of Cancer. Journal International Du Cancer·Leonardo I GreenUNKNOWN HPV Pilot Steering Committee
Nov 29, 2020·BJOG : an International Journal of Obstetrics and Gynaecology·F PesolaP Sasieni
Oct 27, 2020·Journal of Lower Genital Tract Disease·Jesper BondeJeffrey C Andrews
Feb 12, 2021·PloS One·Gry St-MartinMarianne Waldstrøm
Mar 26, 2021·Cancer Cytopathology·Aofei LiChengquan Zhao
Apr 28, 2021·BMC Women's Health·R IbáñezI Oyagüez
Aug 6, 2021·Obstetrics and Gynecology·Jeppe Bennekou SchrollMatejka Rebolj